Programs
CV6 Therapeutics is developing a pipeline of first-in-class therapies designed to improve how widely used treatments perform in cancer and inflammatory disease.
Our programs are built around a novel understanding of uracil-DNA metabolism and are designed to work in combination with existing standards of care, enhancing efficacy without adding toxicity.
Scientific Focus
Our scientific focus centers on uracil-DNA metabolism, a previously underexplored but highly promising therapeutic pathway. By developing first-in-class small molecule drugs that selectively modulate this process, we aim to control abnormal cellular behaviour at its source. Our therapies are specifically designed to work in combination with widely used standard-of-care treatments — enhancing their effectiveness without adding toxicity.
Lorem ipsum dolor sit amet consectetur. In consectetur sollicitudin nibh elit iaculis mauris neque suspendisse. Congue suscipit elementum dolor eros. In sagittis volutpat arcu tortor magnis. Pulvinar tellus tellus varius quis leo proin orci sit. Tellus at sagittis sed mi purus tempus vestibulum eget. Congue mattis amet elit amet.
If CV6-168 performs as expected, it could fundamentally change how we use 5-FU in cancer treatment.
Oncology
CV6 is advancing therapies designed to improve outcomes in cancers where standard treatments remain essential but limited by resistance.
Inflamatory Diseases
CV6 is applying the same scientific approach to inflammatory diseases, including rheumatoid arthritis, where current treatments often fall short.
Pipeline
CV6 is building a pipeline of next-generation therapies designed to transform how established treatments work.
Our lead asset, CV6-168, is currently in Phase 1a clinical trials. Additional programs are advancing toward clinical development, extending this approach into new therapeutic areas.